Merck Canada and the Centre for Vaccine Preventable Diseases (CVPD) Relaunch Collaboration to Advance Vaccine Research and Education


KIRKLAND, QC, February 15, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is pleased to announce the renewal of its support for the Centre for Vaccine Preventable Diseases (CVPD) for 2024. The focus of this collaboration will help drive research and education to shine a light on Canada’s quest to combat preventable diseases through immunization.

Established by the University of Toronto (U of T) in 2019 at the Dalla Lana School of Public Health, the CVPD fosters collaboration and knowledge exchange among more than 50 expert members who hold various leadership positions at local, national, and international levels.

“At the Centre for Vaccine Preventable Diseases (CVPD), we bring together leading experts to answer the biggest vaccine-related questions of today and prepare for the potential challenges of tomorrow,” said Dr. Shelly Bolotin, who serves as Director of the CVPD as well as an Associate Professor at the Dalla Lana School of Public Health.

“We are thrilled to reignite our collaboration with the CVPD in a shared mission to unlock the full potential of vaccines. By fostering multidisciplinary communication, we are positioned to push the boundaries of innovation,” said Jennifer Chan, Executive Director for Policy and Government Relations at Merck Canada.

About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

In Canada, Merck markets a broad range of vaccines, pharmaceutical and animal health products and is one of the top R&D investors in Canada, with investments totaling more than $90 million in 2022 and more than $1.6 billion since 2000. Based in Kirkland, Quebec, Merck employs approximately 635 people across the country. For more information about our operations in Canada, visit and connect with us on LinkedIn and X @MerckCanada.


© 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.